Advertisement
YOU ARE HERE: LAT HomeCollectionsSato Pharmaceutical Co
IN THE NEWS

Sato Pharmaceutical Co

FEATURED ARTICLES
BUSINESS
February 11, 1992
Meditech Pharmaceuticals Inc., an Encino drug company, said in a filing with the Securities and Exchange Commission that it has agreed to grant a Japanese pharmaceutical company exclusive Japanese rights for Meditech's anti-herpes drug, MTCH-24, while the foreign concern conducts human clinical trials on the drug. A payment of $50,000 has been made to Meditech by the Japanese company, Sato Pharmaceutical Co., in connection with the agreement, the SEC filing said.
ARTICLES BY DATE
BUSINESS
February 11, 1992
Meditech Pharmaceuticals Inc., an Encino drug company, said in a filing with the Securities and Exchange Commission that it has agreed to grant a Japanese pharmaceutical company exclusive Japanese rights for Meditech's anti-herpes drug, MTCH-24, while the foreign concern conducts human clinical trials on the drug. A payment of $50,000 has been made to Meditech by the Japanese company, Sato Pharmaceutical Co., in connection with the agreement, the SEC filing said.
Advertisement
BUSINESS
March 10, 1992 | PATRICE APODACA, TIMES STAFF WRITER
About a decade ago, Gerald N. Kern had a comfortable, high-paying job as executive vice president at cosmetics concern Max Factor & Co. One day, an acquaintance introduced Kern to someone who claimed to have found an effective herpes treatment in a drug commonly used as a laxative. Kern paid to have some tests done on the drug and, after adjustments were made to reduce toxicity levels, he decided he was on to something.
Los Angeles Times Articles
|